Jim Cramer, the host of Mad Money, on Tuesday talked about the opening days of earnings season and the market’s uneven behavior.
“The market gets so angry over nothing. It’s just plain irritable, very hard to please, like a 3-year-old child. But when you make it happy, the inner child giggles, and your stocks will soar. Not that you can tell from the averages today. I was hoping that these would be a little more tame, and yes, even logical.”
READ ALSO Jim Cramer Recently Looked At These 16 Stocks and 11 Stocks on Jim Cramer’s Game Plan For This Week
Cramer explained that the market appeared to decide that companies tied to software would be hurt by artificial intelligence rather than helped by it, and as a result, Salesforce, Adobe, and ServiceNow were hit hard again. He added that the hardware side of artificial intelligence moved sharply higher, led by Intel and AMD. He also noted that NVIDIA still failed to attract the same level of enthusiasm, despite its central role in AI hardware. He said that one of the most striking developments of the day was the sudden affection for retail stocks. He observed that after being shunned for about a year, retailers quickly became favorites, and it was surprising how fast that shift occurred. He added that buyers could not seem to find a price level where they were willing to step away from dollar stores and discount chains.
“As I said at the beginning of the year, though, the first two weeks are always a jumbled amalgam of love and hate, too much of both. But the bottom line? Now that earnings season has started, the rehearsals are over, and we’re going to begin to see the reaction to actual numbers. And if it’s anything like JPMorgan, what can I say? It’s showtime.”
Our Methodology
For this article, we compiled a list of 7 stocks that were discussed by Jim Cramer during the episode of Mad Money aired on January 13. We listed the stocks in the order that Cramer mentioned them. We also provided hedge fund sentiment for each stock as of the third quarter of 2025, which was taken from Insider Monkey’s database of 978 hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
7 Stocks on Jim Cramer’s Radar Recently
7. Structure Therapeutics Inc. (NASDAQ:GPCR)
Number of Hedge Fund Holders: 42
Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the stocks on Jim Cramer’s radar recently. When a caller inquired about the stock, Cramer commented:
“Oh, okay, so this is a, they have a deal with Roche, and therefore, I think it’s a legitimate idea, but, boy, the stock fully reflects that deal. I don’t want to touch it. Lilly is still the gold standard.”
Structure Therapeutics Inc. (NASDAQ:GPCR) develops oral small-molecule drugs to treat chronic conditions like obesity and pulmonary fibrosis.
6. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)
Number of Hedge Fund Holders: 34
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is one of the stocks on Jim Cramer’s radar recently. During the lightning round, a caller asked if they should buy more, hold, or sell their position in the stock, and here’s what Cramer had to say in response:
“I like Catalyst Pharmaceuticals. It actually has, by the way, real earnings, and it’s a very inexpensive stock. I think you’ve got a winner.”
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) provides treatments for patients managing rare conditions such as Lambert-Eaton myasthenic syndrome and Duchenne muscular dystrophy. During the episode that aired on March 25, 2025, a caller inquired about the stock and Cramer replied:
“No, I think it’s very good and it’s had a very good year. It’s up more than almost every other drug, any company I follow. Yeah, we did like it. Now remember this [is] still [a] small cap stock and there’s some insider selling, but I do think it’s just a very good situation. We went over that a while ago and it beat the earnings estimates…. They were supposed to earn 55 cents and earned 70 cents. That’s my kind of stock. I think you’re in good shape.”
It should be noted that since the above comment was aired, Catalyst Pharmaceuticals, Inc.’s (NASDAQ:CPRX) stock has declined by around 13%.
